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ABSTRACT
Objectives: A number of observational studies have
reported that, in patients with chronic obstructive
pulmonary disease (COPD), β blockers (BBs) decrease
risk of mortality and COPD exacerbations. To address
important methodological concerns of these studies,
we compared the effectiveness and safety of
cardioselective BBs versus non-dihydropyridine
calcium channel blockers (non-DHP CCBs) in patients
with COPD and acute coronary syndromes (ACS) using
a propensity score (PS)-matched, active comparator,
new user design. We also assessed for potential
unmeasured confounding by examining a short-term
COPD hospitalisation outcome.
Setting and participants: We identified 22 985
patients with COPD and ACS starting cardioselective
BBs or non-DHP CCBs across 5 claims databases from
the USA, Italy and Taiwan.
Primary and secondary outcome measures:
Stratified Cox regression models were used to estimate
HRs for mortality, cardiovascular (CV) hospitalisations
and COPD hospitalisations in each database after
variable-ratio PS matching. Results were combined
with random-effects meta-analyses.
Results: Cardioselective BBs were not associated with
reduced risk of mortality (HR, 0.90; 95% CI 0.78 to
1.02) or CV hospitalisations (HR, 1.06; 95% CI 0.91 to
1.23), although statistical heterogeneity was observed
across databases. In contrast, a consistent, inverse
association for COPD hospitalisations was identified
across databases (HR, 0.54; 95% CI 0.47 to 0.61),
which persisted even within the first 30 days of follow-
up (HR, 0.55; 95% CI 0.37 to 0.82). Results were
similar across a variety of sensitivity analyses,
including PS trimming, high dimensional-PS matching
and restricting to high-risk patients.
Conclusions: This multinational study found a large
inverse association between cardioselective BBs and
short-term COPD hospitalisations. The persistence of
this bias despite state-of-the-art
pharmacoepidemiologic methods calls into question
the ability of claims data to address confounding in
studies of BBs in patients with COPD.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) has profound health impacts world-
wide1 2 and usually coexists with cardiovascu-
lar (CV) morbidity.3–6 CV risk reduction is
Strengths and limitations of this study
▪ A growing body of observational studies sug-
gests that β blockers (BBs) may decrease risk of
mortality and chronic obstructive pulmonary
disease (COPD) exacerbations in patients with
COPD; most studies compared prevalent BB
users to non-users.
▪ This study used an active comparator, new user
cohort design to examine the association
between BBs and clinical outcomes and to
assess potential remaining unmeasured con-
founding using data from five claims databases
in the USA, Italy and Taiwan.
▪ The study applied a variety of sensitivity ana-
lyses, including propensity score (PS) trimming,
an high-dimensional PS matching technique and
restricting to high-risk patients, to evaluate the
consistency of results.
▪ Although this multinational study was conducted
with a common protocol, the inherent variations
in healthcare systems and data structures across
countries necessitated certain database-specific
modifications to the protocol.
▪ Owing to analytic flexibility, we conducted sensi-
tivity analyses in the three US databases only.
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therefore a major focus in COPD management. β block-
ers (BBs) are a cornerstone treatment for improving sur-
vival and reducing CV morbidity in patients with
coronary artery disease.7–10 The cardioprotective bene-
ﬁts of BBs are expected to extend to patients with
COPD. However, those with COPD have generally been
excluded from randomised controlled trials evaluating
the efﬁcacy of BBs in patients experiencing myocardial
infarction (MI).7 9 In addition, while the targets of BBs
in treating CV disease are β-1 receptors predominantly
found in cardiac tissues, BBs can also block β-2 receptors
in the respiratory system, causing bronchospasm and
increasing the risk of COPD exacerbations.11 Therefore,
in clinical practice, physicians may be reluctant to pre-
scribe BBs to patients with COPD.6 12 One study found
that, among patients hospitalised for acute MI, those
with COPD had 56% lower odds of being treated with
BBs as compared to those without COPD.12
Despite these safety concerns, a growing body of obser-
vational studies suggests that BBs may have cardioprotec-
tive effects in COPD patients.13–22 One meta-analysis of
observational studies reported a 36% reduction in all-
cause mortality associated with BB use in patients with
coronary heart disease and COPD.23 However, these
studies have important methodological limitations. In
particular, most of these studies focused on prevalent
users of BBs13–22 and used non-users of BBs as the com-
parator group.13–21 Patients who remain on BB treatment
for a long time may be less susceptible to an outcome of
interest as compared to those just starting the drug. The
prevalent user design is therefore vulnerable to biases due
to depletion of susceptible patients.24 25 Treated patients
may also differ from untreated patients in important ways,
which can create strong confounding, especially when the
indication for treatment is a risk factor for the outcome(s)
of interest.24 The non-user comparator approach is also
vulnerable to immortal time bias.26 These methodological
issues may explain the paradoxical COPD hospitalisation
ﬁndings reported in these studies and perhaps even the
reported survival advantage.
Drug safety and comparative effectiveness studies are
increasingly using multiple databases across various
countries.27–29 The larger sample size afforded by multi-
databases studies facilitates the application of robust
study designs and, by using a common protocol, such
studies enable investigators to leverage differences in the
healthcare systems in the assessment of unmeasured
confounding, treatment effect heterogeneity and gener-
alisability across diverse populations, while holding con-
stant the design and analytic approach. In the present
study, we used multiple databases from three countries
to: (1) address important shortcomings of prior studies
by comparing the effectiveness and safety of BBs in
patients with acute coronary syndromes (ACS) and
COPD using a propensity score (PS)-matched, active
comparator, new user cohort design; and (2) assess for
potential remaining unmeasured confounding by exam-
ining a short-term COPD hospitalisation outcome.
METHODS
Data source
We identiﬁed eligible cohorts from ﬁve databases in the
USA, Italy and Taiwan: (1) the Optum Research
Database (Optum); (2) pharmacy claims data from the
Pharmaceutical Assistance Contract for the Elderly
program (PACE) in Pennsylvania linked to Medicare
claims data; (3) pharmacy claims data from the
Pharmaceutical Assistance for the Aged and Disabled
program in New Jersey (PAAD) linked to Medicare
claims data; (4) the population-based Regione
Emilia-Romagna, Italy, database (RER) and (5) the
population-based Taiwan National Health Insurance
database (NHI). These databases contain demographic
and enrolment records, hospital admissions, outpatient
visits (except in RER), outpatient pharmacy dispensing
claims and death information. These ﬁve databases
cover the period from 1994 through the end of 2013
and represent diverse source populations across coun-
tries with different health insurance programmes (see
the online supplementary materials for details).
Study population and study drugs
From each database, we identiﬁed patients who were
hospitalised for ACS, had a COPD diagnosis before the
ACS hospitalisation discharge date and initiated a cardi-
oselective BB or non-dihydropyridine calcium channel
blocker (non-DHP CCB) within 90 days following hos-
pital discharge (see the online supplementary materials
for details). Codes used to identify study drugs are pro-
vided in online supplementary table S1. The index date
was deﬁned as the date of the ﬁrst postdischarge pre-
scription of a study drug. To focus on initiators, patients
with any use of these drugs before the ﬁrst postdischarge
prescription were excluded. Cardioselective BBs were
chosen as the exposure of interest in alignment with
prior studies.13–22 Initiators of non-DHP CCBs were
selected as the referent group since guidelines recom-
mend non-DHP CCB treatment in patients with ACS
who have a contraindication to BBs and have no other
contraindications (eg, severe left ventricular
dysfunction).30 31
We excluded patients without continuous enrolment
for at least 180 days before the ACS hospitalisation
admission date (see the online supplementary materials
for details), those with age <20 years (Optum, RER,
NHI) or 65 years (PACE, PAAD) or more than 120 years,
and those who simultaneously initiated study drugs from
both exposure groups on the index date.
Outcomes and follow-up
We selected all-cause mortality and CV hospitalisations
as outcomes of interest. CV hospitalisations were deﬁned
as ﬁrst hospitalisation for a composite CV event, includ-
ing acute MI, unstable angina and congestive heart
failure (CHF) following the index date. We conducted
analyses for the composite CV event and individual com-
ponents of the outcomes separately. We also examined
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hospitalisation for COPD as an outcome. CV and COPD
hospitalised events were deﬁned using validated claims-
based algorithms with positive predictive values of 80%
for acute MI,32 88–94% for CHF33 and 86% for COPD34
(see the online supplementary materials for outcome
ascertainment; all outcomes were based on primary
inpatient diagnoses). While animal models have sug-
gested that chronic BB use may upregulate β-2 adreno-
ceptors and attenuate pulmonary inﬂammation,35 36
meta-analyses of randomised trials have found that there
is no signiﬁcant effect of cardioselective BB on pulmon-
ary function in the short term (single dose to 4
months).37 38 We therefore assessed for the presence of
bias by using a short-term COPD hospitalisation
outcome as a negative control, deﬁned as a COPD hos-
pitalisation within 30 days following the index date. We
assumed that, even if BBs improve COPD in the long
term, a large apparent protective association in the short
term would not be causal and would reﬂect bias, such as
confounding due to unmeasured baseline differences
between treatment groups.
In the primary ‘ﬁrst exposure carried forward’ ana-
lysis, we followed patients from the index date to the
earliest of outcome occurrence, death, disenrollment
from the health insurance programme or the end of
study. In the secondary ‘as-treated’ analysis, follow-up
ended on the ﬁrst of treatment discontinuation or
change, outcome occurrence, death, disenrollment from
the health insurance programme or the end of study.
Treatment discontinuation was deﬁned using a grace
period of up to 14 days between the end of one prescrip-
tion and the date of the next prescription, if any.
Treatment change was deﬁned as a dispensation of a
drug in the other exposure group. Given the absence of
information on days supply in the RER database, we
assigned a proxy based on the WHO’s Deﬁned Daily
Dose methodology (online supplementary table S1).
This approach has shown good concordance with days
supply for chronically used medications.39
Covariates
Information on potential confounders included demo-
graphic data, year of index date, enrolment duration,
resource utilisation, comorbidities and other medication
use. Resource utilisation was evaluated during the
180-day baseline period preceding the index date.
CV-related comorbidities and medication use were
assessed in two separate periods: a chronic phase before
the ACS hospitalisation admission date (data were traced
back as far as possible within each database); and an
acute phase between the ACS hospitalisation date and
the index date. Non-CV comorbidities and medication
use were evaluated using all available data prior to the
index date. Using all available claims information has
been found to better reduce bias under most conditions
as compared to a ﬁxed look-back period.40 41 Details on
covariate ascertainment are provided in online
supplementary tables S2 and S3.
Statistical analysis
Using the predeﬁned covariates described above, we esti-
mated baseline PSs using logistic regression models to
predict the probability of receiving cardioselective BBs
versus non-DHP CCBs. Non-categorical covariates (eg,
age) were included in the PS model as linear terms.
Since we had many more cardioselective BB initiators
than non-DHP CCB initiators, we conducted variable-
ratio matching (up to 10 cardioselective BB users to
each non-DHP CCB user) using a nearest-neighbour
algorithm with a maximum matching caliper of 0.01 on
the PS scale.42
Variable-ratio matching produces covariate balance
within matched sets but not marginally in the overall
matched population.42 We therefore randomly sampled
one cardioselective BB user from each set of patients
matched to each non-DHP CCB user and examined
whether adequate balance in covariates was achieved
between treatment groups using standard differences43
among this sample (1:1 random-sample matched
cohort). We used Cox proportional hazard models to
estimate HRs and 95% CIs. To account for the variable-
ratio matching, the Cox model was stratiﬁed on
PS-matched sets.
We identiﬁed study cohorts, extracted information on
variables, ﬁt PS models and performed PS matching sep-
arately within each database. We computed standardised
differences across the databases for each variable using
pooled means and SDs. The random-effects
meta-analysis was used to generate summary estimates
across all databases. Statistical heterogeneity across data-
bases was quantiﬁed using the I2 statistic.
Sensitivity and subgroup analyses
To mitigate potential unmeasured confounding, four
sensitivity analyses were performed in the US databases.
First, the maximum matching caliper was reduced to
0.005. Second, before PS matching, asymmetric PS trim-
ming44 was applied to exclude those with PS values less
than the 2.5th centile or greater than the 97.5th centile
of the PS distribution in cardioselective BB users and
non-DHP CCB users, respectively. Third, high-
dimensional PSs (hd-PSs) were used to identify and
include an additional 100 empirically identiﬁed variables
in the PS model.42 45 Finally, we restricted to high-risk
patients, deﬁned as those with COPD hospitalisations
and use of bronchodilators or inhaled corticosteroids in
the window between 180 days before the index hospital
admission date and the index date. To examine the
inﬂuence of prescribing patterns and treatment strat-
egies over time, we also conducted subgroup analyses by
year of the index date.
RESULTS
Patients
Among 22 985 eligible patients, 18 406 initiated cardio-
selective BBs (80.1%) and 4579 initiated non-DHP CCBs
Dong Y-H, et al. BMJ Open 2017;7:e012997. doi:10.1136/bmjopen-2016-012997 3
Open Access
group.bmj.com on September 13, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
(18.9%) (ﬁgure 1 and see online supplementary table
S4). Most patients (>80%) started treatment within
30 days after the ACS hospitalisation discharge. The
mean age of the cohort was 71 years and 59% were
men. In general, non-DHP CCB initiators were older
and had a longer length of stay for the index ACS hospi-
talisation, a longer history of COPD and higher resource
utilisation. Cardioselective BB initiators were more likely
to have received coronary revascularisation procedures,
have had a diagnosis of MI, peripheral vascular disease
and hyperlipidaemia and have used ACE inhibitors,
ﬁbrates and statins. Non-DHP CCB initiators were more
likely to have had a diagnosis of angina, arrhythmia and
CHF and taken antihypertensive agents, nitrates, antiar-
rhythmic agents and antiplatelet agents. Non-DHP CCB
initiators were also more likely to have had asthma and
used bronchodilators or corticosteroids (table 1 and see
online supplementary table S5a–S5e).
The PS-matched cohort included 11 479 cardioselec-
tive BB initiators and 3588 non-DHP CCB initiators
(66% of the total study cohort). Most, but not all, covari-
ates had standardised differences of <0.1 in the matched
cohort with random sampling of comparator patients
(table 1 and see online supplementary table S5a–S5e).
Summaries of the PS distributions across study drugs
and databases are provided in online supplementary
table S6.
Follow-up and incidence rates
The mean follow-up duration ranged from 1.9 to
3.5 years across databases, with 7489 death, 4970 CV hos-
pitalisation and 1829 COPD hospitalisation events.
Incidence rates of individual outcomes for each treat-
ment group are presented in table 2 and online
supplementary table S7.
All-cause mortality and CV hospitalisations
In the primary analysis considering ﬁrst exposure
carried forward, the crude HRs comparing cardioselec-
tive BBs to non-DHP CCBs on all-cause mortality and
CV hospitalisations were 0.73 (95% CI 0.65 to 0.83) and
0.98 (95% CI 0.84 to 1.14), respectively. After PS match-
ing, the adjusted HRs were 0.90 (95% CI 0.78 to 1.02)
for mortality and 1.06 (95% CI 0.91 to 1.23) for CV
Figure 1 Flow chart of the study
cohort assembly. ACS, acute
coronary syndromes; BBs, β
blockers; COPD, chronic
obstructive pulmonary disease;
DHP CCBs, dihydropyridine
calcium channel blockers. N and
n represented number of patient
episodes and number of patients
remained and excluded in each
step.
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Table 1 Selected baseline demographics, resource utilisation, comorbidities and medication use between cardioselective BB
or bon-DHP CCB initiators*
Before matching After matching
Total study cohort (n=22 985)
1:1 Random-sample† matched cohort
(n=7176)
Cardioselective
BBs (n=18 406)
Non-DHP
CCBs (n=4579) STD
Cardioselective
BBs (n=3588)
Non-DHP
CCBs (n=3588) STD
Age, mean (SD) 70.4 (9.9) 73.8 (10.2) −0.34 73.7 (10.2) 73.5 (10.4) 0.02
Male, % 59.6 55.4 0.09 56.1 55.7 0.01
Length of stay of ACS
hospitalisation, day,
mean (SD)
8.6 (7.9) 10.5 (12.6) −0.18 10.0 (11.4) 10.2 (12.4) −0.02
COPD duration, day,
mean (SD)
998.1 (773.7) 1374.0 (967.6) −0.43 1384.4 (962.9) 1367.2 (988.1) 0.02
Resource utilisation
Number of hospitalisation
due to any episodes, mean
(SD)
1.4 (0.8) 1.6 (1.0) −0.25 1.6 (1.0) 1.6 (1.0) 0.01
Number of outpatient visits
due to any episodes, mean
(SD)
8.2 (6.2) 14.5 (9.6) −0.78 14.0 (9.2) 13.9 (9.4) 0.02
Number of outpatient visits
due to CV episodes,‡ mean
(SD)
3.9 (4.3) 5.2 (4.9) −0.29 5.4 (4.8) 5.3 (4.9) 0.02
Number of outpatient visits
due to pulmonary-related
episodes,§ mean (SD)
1.2 (2.6) 2.7 (3.9) −0.44 2.0 (3.6) 2.1 (3.2) −0.01
Number of drugs, mean
(SD)
14.4 (6.7) 21.0 (9.4) −0.81 20.4 (9.3) 20.1 (9.0) 0.03
Comorbidities, %
Before the ACS admission date
MI 17.3 17.1 0.01 18.3 17.5 0.02
PTCA 4.7 6.6 −0.09 7.0 7.0 <0.01
Stent 3.0 2.4 0.04 2.6 2.8 −0.01
CABG 1.1 1.0 0.01 1.2 1.1 0.01
Haemorrhagic stroke 1.8 2.8 −0.07 2.8 2.8 <0.01
Ischaemic stroke 12.5 14.3 −0.06 14.8 14.7 <0.01
TIA 10.3 12.1 −0.06 12.2 12.2 <0.01
Between the ACS admission date and the index date
MI 76.3 58.2 0.40 62.2 62.8 −0.01
PTCA 44.0 25.9 0.41 29.1 30.4 −0.03
Stent 37.0 16.0 0.52 17.9 18.3 −0.01
CABG 17.3 7.8 0.30 8.7 9.1 −0.01
Haemorrhagic stroke 0.5 0.6 −0.01 0.5 0.6 −0.02
Ischaemic stroke 4.7 4.5 0.01 5.0 4.5 0.02
TIA 2.3 1.7 0.04 1.6 2.0 −0.02
Before the index date
Hypertension 82.0 81.0 0.03 83.0 82.3 0.02
Angina 52.1 62.8 −0.22 60.7 59.8 0.02
Ischaemic heart disease 86.1 84.2 0.06 84.9 84.5 0.01
Cardiac dysrhythmia 44.1 50.8 −0.14 49.7 48.9 0.02
Atrial fibrillation 19.1 25.7 −0.17 25.4 24.4 0.02
CHF 45.3 53.7 −0.18 53.8 53.7 <0.01
Cerebrovascular disease 36.9 38.8 −0.04 39.4 39.5 <0.01
PVD 18.4 12.7 0.21 13.3 13.1 0.01
Disorders of lipid
metabolism
65.5 52.9 0.27 56.9 56.1 0.02
Diabetes mellitus 41.1 42.4 −0.03 44.3 43.6 0.01
Asthma 23.3 40.5 −0.40 37.0 35.9 0.02
Continued
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hospitalisations. We observed substantial statistical het-
erogeneity across databases, with HRs and 95% CIs for
mortality below one in the PACE and RER databases. In
the as-treated analysis, the adjusted HRs for mortality
and CV hospitalisations were 0.80 (95% CI 0.67 to 0.96)
and 1.07 (95% CI 0.85 to 1.36), respectively. We did not
observe statistical heterogeneity for mortality, although
the HR in the Taiwan NHI database was statistically sig-
niﬁcantly <1 (0.70; 95% CI 0.67 to 0.96) (table 3). HRs
for CV hospitalisations due to acute MI, unstable angina
and CHF were similar to those for the composite out-
comes (see online supplementary table S8).
Table 1 Continued
Before matching After matching
Total study cohort (n=22 985)
1:1 Random-sample† matched cohort
(n=7176)
Cardioselective
BBs (n=18 406)
Non-DHP
CCBs (n=4579) STD
Cardioselective
BBs (n=3588)
Non-DHP
CCBs (n=3588) STD
Medication use, %
Before the ACS admission date
ACEIs/ARBs/renin
inhibitors
51.6 56.5 −0.10 58.2 57.6 0.01
Non-cardioselective BBs 19.0 32.2 −0.37 33.9 32.7 0.03
DHP CCBs 35.4 46.0 −0.24 47.5 47.1 0.01
Diuretics 44.8 56.0 −0.23 56.2 55.3 0.02
Other antihypertensive
agents
15.9 24.9 −0.26 25.3 25.0 0.01
Nitrates 30.2 46.8 −0.36 45.9 45.8 <0.01
Antiarrhythmic agents 7.2 11.3 −0.14 10.5 10.3 <0.01
Digoxin 9.3 16.6 −0.23 14.7 15.0 −0.01
Antiplatelet agents 33.1 51.1 −0.48 50.9 50.7 0.01
Anticoagulants 7.0 7.6 −0.02 8.5 7.5 0.04
Fibrates/statins 37.2 32.8 0.10 35.7 35.1 0.01
Between the ACS admission date and the index date
ACEIs ARBs/renin
inhibitors
48.5 36.2 0.26 41.9 40.3 0.03
Non-cardioselective BBs 4.2 8.7 −0.23 9.2 8.7 0.02
DHP CCBs 11.6 8.8 0.10 10.7 10.3 0.01
Diuretics 27.1 29.4 −0.05 30.9 30.0 0.02
Other antihypertensive
agents
3.3 4.2 −0.06 4.1 4.4 −0.01
Nitrates 47.5 59.7 −0.25 59.2 59.0 <0.01
Antiarrhythmic agents 6.2 7.1 −0.04 6.9 7.0 <0.01
Digoxin 6.1 10.5 −0.17 9.0 9.4 −0.02
Antiplatelet agents 60.6 56.9 0.10 59.5 59.8 −0.01
Anticoagulants 6.1 6.6 −0.02 7.2 6.6 0.03
Fibrates/statins 48.2 25.6 0.51 29.4 29.4 <0.01
Before the index date
Antidiabetic agents 27.1 27.2 <0.01 29.4 29.3 <0.01
Short-acting
bronchodilators
34.3 49.8 −0.32 45.7 44.2 0.03
Long-acting
bronchodilators
19.6 27.7 −0.21 24.9 23.6 0.03
ICS 23.8 34.3 −0.25 30.8 29.6 0.03
Oral corticosteroids 44.6 64.4 −0.45 61.4 61.4 <0.01
Oral bronchodilators 25.8 61.7 −1.16 57.0 56.7 0.01
*Presenting as summary estimates for mean, SD and STD across databases.
†One randomly sampled cardioselective BBs user: 1 non-DHP CCBs user in each matched subset.
‡CV episodes included: MI, coronary revascularisation (PTCA, stent, CABG), haemorrhagic stroke, ischaemic stroke, TIA, hypertension,
angina, IHD, cardiac dysrhythmia, atrial fibrillation, CHF, cerebrovascular disease and PVD.
§Pulmonary-related episodes included COPD, asthma, pneumonia, influenza and acute bronchitis.
ACEIs, ACE inhibitors; ACS, acute coronary syndromes; ARBs, angiotensin II receptor blockers; BBs, β blockers; CABG, coronary artery
bypass graft surgery; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; Cox, cyclooxygenase; CV, cardiovascular;
DHP CCBs, dihydropyridine calcium channel blockers; ICS, inhaled corticosteroids; IHD, ischaemia heart disease; MI, myocardial infarction;
NSAIDs, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors; PTCA, percutaneous transluminal coronary angioplasty; PVD,
peripheral vascular disease; STD, standardised differences; TIA, transient ischaemic attack.
6 Dong Y-H, et al. BMJ Open 2017;7:e012997. doi:10.1136/bmjopen-2016-012997
Open Access
group.bmj.com on September 13, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Table 2 Follow-up and outcome event rates for cardioselective BB or non-DHP CCB initiators
Cardioselective BBs (n=18 406) Non-DHP CCBs (n=4579)
Database
Number of
patients
Number of
events
Follow-up
person-years
Crude incidence
(per 1000 person-years)
Number of
patients
Number of
events
Follow-up
person-years
Crude incidence
(per 1000 person-years)
All-cause mortality*
US Optum 6383 384 12 298 31.2 (28.3 to 34.5) 296 35 445 78.7 (56.5 to 109.5)
US PACE 3372 1909 11 616 164.3 (157.1 to 171.9) 909 717 3301 217.2 (201.9 to 233.7)
US PAAD 2108 957 6264 152.8 (143.4 to 162.8) 560 353 2128 165.9 (149.4 to 184.1)
Italy RER 2489 989 8042 123.0 (115.6 to 130.9) 565 352 2181 161.4 (145.4 to 179.2)
Taiwan NHI 4054 1003 11 403 88.0 (82.5 to 93.4) 2249 790 6491 121.7 (113.2 to 130.2)
Summary estimate 96.9 (61.9 to 151.8) 145.0 (111.1 to 189.3)
CV hospitalisations*
US Optum 6383 476 11 534 41.3 (37.7 to 45.2) 296 27 402 67.2 (46.1 to 97.9)
US PACE 3372 1144 9155 125.0 (117.9 to 132.4) 909 312 2582 120.9 (108.2 to 135.0)
US PAAD 2108 633 4986 127.0 (117.4 to 137.2) 560 169 1724 98.0 (84.3 to 114.0)
Italy RER 2489 761 6267 121.4 (113.1 to 130.4) 565 225 1608 139.9 (122.8 to 159.4)
Taiwan NHI 4054 816 10 055 81.2 (75.6 to 86.7) 2249 407 5763 70.3 (63.4 to 77.1)
Summary estimate 91.7 (63.4 to 132.5) 96.8 (72.1 to 129.9)
COPD hospitalisations*
US Optum 6383 192 12 035 15.95 (13.9 to 18.4) 296 35 395 88.5 (63.6 to 123.3)
US PACE 3372 274 11 023 24.9 (22.1 to 28.0) 909 214 2808 76.2 (66.7 to 87.1)
US PAAD 2108 155 5938 26.1 (22.3 to 30.6) 560 146 1823 80.1 (68.1 to 94.2)
Italy RER 2489 240 7529 31.9 (28.1 to 36.2) 565 145 1804 80.4 (68.3 to 94.6)
Taiwan NHI 4054 154 11 145 13.8 (11.6 to 16.0) 2249 274 6022 45.5 (40.1 to 50.9)
Summary estimate 21.5 (15.9 to 29.1) 71.5 (54.6 to 93.6)
BBs, β blockers; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DHP CCBs, dihydropyridine calcium channel blockers; NHI, National Health Insurance; PAAD, Pharmacy
Assistance for the Aged and Disabled; PACE, Pharmacy Assistance Contract for the Elderly; RER, Emilia-Romagna Region.
*Based on the analysis that considered first exposure carried forward.
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COPD hospitalisation outcome
In the ﬁrst exposure carried forward and as-treated ana-
lyses, the crude HRs comparing cardioselective BBs to
non-DHP CCBs for COPD hospitalisations were 0.30
(95% CI 0.26 to 0.36) and 0.23 (95% CI 0.19 to 0.27),
respectively. After PS matching, HRs were still substan-
tially <1: 0.54 (95% CI 0.47 to 0.61) for the ﬁrst expos-
ure carried forward analysis and 0.54 (95% CI 0.41 to
0.70) for the as-treated analysis (table 3). The adjusted
HR for COPD hospitalisations restricted to the ﬁrst
30 days of follow-up was 0.55 (95% CI 0.37 to 0.82)
(table 4).
Sensitivity and subgroup analyses
Sensitivity analyses applying a narrower PS caliper, asym-
metric PS trimming, hd-PS matching and restricting to
high-risk patients did not materially change the primary
analysis results. The hd-PS sensitivity analysis yielded an
estimate for COPD hospitalisations that was closest to
the null at 0.62 (95% CI 0.51 to 0.76) (table 5). See
online supplementary table S9a–S9c for baseline
characteristics of patients in sensitivity analyses. The asso-
ciation of cardioselective BBs and each outcome was
similar across periods before 2000, between 2001–2005
and after 2006 (see online supplementary table S10).
DISCUSSION
This large-scale, multinational study employed
state-of-the-art pharmacoepidemiologic methods, includ-
ing an active comparator, new user cohort design, PS
trimming and hd-PS matching, and found potential evi-
dence of bias when comparing cardioselective BBs and
non-DHP CCBs in patients with ACS and COPD as
reﬂected by an apparent large protective effect of cardi-
oselective BBs on a short-term COPD hospitalisation
outcome. The observed association was highly consistent
across different methods used to address confounding
and across the ﬁve databases encompassing diverse
populations from different health systems.
Cardioselective BBs were not associated with reduced
risk of mortality or CV hospitalisations, although statis-
tical heterogeneity was observed across data sources.
While there may be several reasons for the apparent
large protective effect of cardioselective BBs on a short-
term COPD hospitalisation outcome, we believe bias due
Table 3 Risk of all-cause mortality, CV hospitalisations and COPD hospitalisations comparing cardioselective BB versus
non-DHP CCB initiators
Crude HR (95% CI)
HR after PS
matching (95% CI) Crude HR (95% CI)
HR after PS
matching (95% CI)
Database First exposure carried forward As-treated analysis
All-cause mortality
US Optum 0.42 (0.30 to 0.60) 1.05 (0.65 to 1.68) 0.71 (0.31 to 1.61) 1.23 (0.47 to 3.20)
US PACE 0.76 (0.69 to 0.82) 0.86 (0.76 to 0.98) 0.70 (0.57 to 0.87) 0.90 (0.64 to 1.27)
US PAAD 0.91 (0.81 to 1.03) 1.12 (0.93 to 1.36) 0.94 (0.69 to 1.30) 0.93 (0.58 to 1.52)
Italy RER 0.74 (0.66 to 0.84) 0.74 (0.64 to 0.85) 0.86 (0.68 to 1.11) 0.74 (0.52 to 1.05)
Taiwan NHI 0.71 (0.65 to 0.78) 0.90 (0.80 to 1.02) 0.63 (0.51 to 0.78) 0.70 (0.51 to 0.96)
Summary estimate 0.73 (0.65 to 0.83) 0.90 (0.78 to 1.02) 0.75 (0.64 to 0.87) 0.80 (0.67 to 0.96)
I2, % 81.9 68.5 35.1 0.0
P for heterogeneity <0.001 0.013 0.187 0.649
CV hospitalisations
US Optum 0.70 (0.47 to 1.02) 0.96 (0.59 to 1.56) 0.76 (0.41 to 1.39) 0.84 (0.41 to 1.71)
US PACE 1.01 (0.89 to 1.14) 1.03 (0.87 to 1.22) 0.96 (0.81 to 1.13) 1.09 (0.85 to 1.39)
US PAAD 1.16 (0.97 to 1.37) 1.30 (1.03 to 1.65) 1.27 (0.97 to 1.67) 1.41 (0.95 to 2.11)
Italy RER 0.80 (0.69 to 0.93) 0.86 (0.73 to 1.01) 0.77 (0.59 to 0.99) 0.75 (0.56 to 1.02)
Taiwan NHI 1.12 (1.00 to 1.26) 1.17 (1.00 to 1.36) 1.06 (0.87 to 1.29) 1.31 (1.00 to 1.71)
Summary estimate 0.98 (0.84 to 1.14) 1.06 (0.91 to 1.23) 0.98 (0.83 to 1.15) 1.07 (0.85 to 1.36)
I2, % 78.2 63.8 51.0 59.5
P for heterogeneity 0.001 0.026 0.086 0.043
COPD hospitalisations
US Optum 0.19 (0.13 to 0.27) 0.54 (0.37 to 0.87) 0.16 (0.09 to 0.31) 0.53 (0.19 to 1.47)
US PACE 0.32 (0.27 to 0.39) 0.51 (0.39 to 0.67) 0.22 (0.17 to 0.29) 0.54 (0.34 to 0.86)
US PAAD 0.30 (0.24 to 0.38) 0.45 (0.32 to 0.62) 0.23 (0.15 to 0.34) 0.54 (0.30 to 0.98)
Italy RER 0.38 (0.31 to 0.48) 0.56 (0.44 to 0.73) 0.29 (0.19 to 0.46) 0.40 (0.20 to 0.77)
Taiwan NHI 0.30 (0.25 to 0.37) 0.60 (0.47 to 0.78) 0.24 (0.16 to 0.34) 0.65 (0.38 to 1.13)
Summary estimate 0.30 (0.26 to 0.36) 0.54 (0.47 to 0.61) 0.23 (0.19 to 0.27) 0.54 (0.41 to 0.70)
I2, % 62.0 0.0 0.0 0.0
P for heterogeneity 0.030 0.721 0.639 0.877
BBs, β blockers; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DHP CCBs, dihydropyridine calcium channel blockers;
NHI, National Health Insurance; PAAD, Pharmacy Assistance for the Aged and Disabled; PACE, Pharmacy Assistance Contract for the
Elderly; PS, propensity score; RER, Emilia-Romagna Region.
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to unmeasured confounding is a major contributor. We
cannot exclude the possibility that CCBs may worsen
oxygenation and lead to an increased risk of COPD hos-
pitalisations.46 47 However, this likely would not fully
explain the observed association. In addition, this large
ﬁnding is not likely to be due to chance given that we
observed consistent point estimates across databases and
statistical approaches and the CIs around the estimates
were narrow. In expectation, if there is non-differential
exposure or outcome misclassiﬁcation, it would lead to
bias towards the null and therefore it is unlikely to
explain the observed ﬁndings. Moreover, our ﬁnding is
unlikely to be explained by surveillance bias because
healthcare professionals or patients themselves may be
more attuned to respiratory-related effects when cardio-
selective BBs are given. Any resulting bias would be in
the opposite direction of the observed association. It is
possible that, since clinicians are more likely to prescribe
CCBs than BBs to patients with more severe COPD, an
anchoring bias48 could occur where CCB-treated
patients may be more closely monitored for respiratory
function and COPD exacerbations. However, our study
outcomes were all deﬁned by requiring hospitalisation,
reducing the likelihood that such differential surveil-
lance could fully explain the results. We did observe
important differences between cardioselective BB and
non-DHP CCB initiators at baseline. As compared to
non-DHP CCB initiators, cardioselective BB initiators
were younger, had less health resource utilisation and
had less prior COPD medication use. While we were
able to account for these differences in measured
factors, we suspect that other important unmeasured
risk factors for COPD hospitalisation remained imbal-
anced, such as differences in COPD severity and
Table 4 Results for 30-day COPD hospitalisations
comparing cardioselective BB versus non-DHP CCB
initiators*
Database
Crude HR
(95% CI)
HR after PS
matching (95% CI)
US Optum 0.28 (0.06 to 1.23) 1.33 (0.17 to 10.70)
US PACE 0.27 (0.15 to 0.47) 0.70 (0.31 to 1.54)
US PAAD 0.19 (0.09 to 0.37) 0.43 (0.18 to 0.99)
Italy RER 0.22 (0.10 to 0.48) 0.37 (0.16 to 0.84)
Taiwan NHI 0.28 (0.15 to 0.51) 0.67 (0.32 to 1.38)
Summary
estimate
0.25 (0.18 to 0.34) 0.55 (0.37 to 0.82)
*Based on the analysis that considered first exposure carried
forward.
BBs, β blockers; COPD, chronic obstructive pulmonary disease;
DHP CCBs, dihydropyridine calcium channel blockers; NHI,
National Health Insurance; PAAD, Pharmacy Assistance for the
Aged and Disabled; PACE, Pharmacy Assistance Contract for the
Elderly; PS, propensity score; RER, Emilia-Romagna Region.
Table 5 Results of sensitivity analyses comparing cardioselective BB versus non-DHP CCB initiators in three US
databases*
Type of analysis Main analysis†
Sensitivity analysis
PS matching
caliper of 0.005
Asymmetric PS
trimming
hd-PS with
additional 100
empirical covariates
Restricting to
high-risk patients
Database HR after PS matching (95% CI)
All-cause mortality
US Optum 1.05 (0.65 to 1.68) 1.06 (0.65 to 1.73) 0.92 (0.54 to 1.56) 1.02 (0.61 to 1.72) 1.11 (0.53 to 2.33)
US PACE 0.86 (0.76 to 0.98) 0.85 (0.75 to 0.97) 0.85 (0.74 to 0.97) 0.86 (0.76 to 0.99) 0.91 (0.73 to 1.14)
US PAAD 1.12 (0.93 to 1.36) 1.13 (0.93 to 1.36) 1.00 (0.82 to 1.23) 1.16 (0.95 to 1.40) 1.02 (0.73 to 1.42)
Summary
estimate
0.98 (0.80 to 1.21) 0.98 (0.78 to 1.23) 0.90 (0.80 to 1.00) 0.99 (0.78 to 1.26) 0.95 (0.80 to 1.14)
CV hospitalisations
US Optum 0.96 (0.59 to 1.56) 0.92 (0.56 to 1.49) 0.81 (0.48 to 1.38) 0.99 (0.60 to 1.65) 0.70 (0.31 to 1.62)
US PACE 1.03 (0.87 to 1.22) 1.03 (0.86 to 1.22) 1.02 (0.85 to 1.23) 1.01 (0.84 to 1.21) 1.03 (0.76 to 1.39)
US PAAD 1.30 (1.03 to 1.65) 1.33 (1.04 to 1.69) 1.31 (1.01 to 1.69) 1.10 (0.86 to 1.43) 1.31 (0.82 to 2.10)
Summary
estimate
1.11 (0.94 to 1.32) 1.11 (0.91 to 1.36) 1.08 (0.87 to 1.35) 1.04 (0.90 to 1.19) 1.06 (0.83 to 1.35)
COPD hospitalisations
US Optum 0.54 (0.37 to 0.87) 0.59 (0.35 to 0.97) 0.67 (0.37 to 1.23) 0.77 (0.44 to 1.34) 0.61 (0.30 to 1.22)
US PACE 0.51 (0.39 to 0.67) 0.52 (0.40 to 0.67) 0.50 (0.37 to 0.66) 0.61 (0.46–0.80) 0.56 (0.39 to 0.81)
US PAAD 0.45 (0.32 to 0.62) 0.46 (0.33 to 0.64) 0.36 (0.25 to 0.51) 0.59 (0.41 to 0.84) 0.52 (0.31 to 0.88)
Summary
estimate
0.50 (0.41 to 0.69) 0.51 (0.42 to 0.61) 0.47 (0.35 to 0.64) 0.62 (0.51 to 0.76) 0.56 (0.42 to 0.73)
*Based on the analysis that considered first exposure carried forward.
†Main analysis used maximum PS matching caliper of 0.01, no PS trimming and a predefined PS model.
BBs, β blockers; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DHP CCBs, dihydropyridine calcium channel blockers;
hd, high dimensional; NHI, National Health Insurance; PAAD, Pharmacy Assistance for the Aged and Disabled; PACE, Pharmacy Assistance
Contract for the Elderly; PS, propensity score; RER, Emilia-Romagna Region.
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smoking status, which therefore led to a bias due to
unmeasured confounding. However, since these vari-
ables are not captured in claims data, we cannot verify
this.
In terms of pharmacological effects of BB treatment,
animal models and meta-analyses of published rando-
mised trials do not support the notion that BB treatment
can have such a large and immediate effect on respira-
tory function.35–38 A prior study did not observe signiﬁ-
cant differences in pulmonary function or symptoms of
wheezing or dyspnoea after acute administration of BB
treatment in patients with cardiac disease and COPD.49
Our study, however, showed an apparent 45% reduction
in COPD exacerbations comparing cardioselective BB to
non-DHP CCB, which is similar to the 40% reduction
observed in other observational studies in which BB use
was compared to non-BB use.12 15 17 18 20 21 23 This
apparent beneﬁt associated with BB treatment is even
considerably larger than that conferred by the most
effective known treatment—long-acting bronchodilators
—which reduce COPD hospitalisations by only 14–
17%.50 51 An ongoing randomised, double-blind,
placebo-controlled trial is examining whether BB treat-
ment can prevent COPD exacerbations.52 The results
will help determine the extent to which the observed
association between BB treatment and reduced COPD
hospitalisation is due to actual clinical beneﬁts of BBs
versus bias in observational studies. Our study suggests
the latter to be a major contributor.
A prior meta-analysis of observational studies sug-
gested that BB use was associated with a 36% reduction
in mortality in patients with coronary diseases and
COPD.23 However, our PS-matched as-treated analysis of
mortality yielded an HR of 0.80 (95% CI 0.67 to 0.96)
and our PS-matched ﬁrst exposure carried forward ana-
lysis yielded an HR of 0.90 (95% CI 0.78 to 1.02). Our
results also suggested no beneﬁt of cardioselective BBs
on CV hospitalisations. These ﬁndings were similar to a
recent population-based observational study that
included 107 902 patients with COPD (only 3% of
whom having concomitant MI diagnosis) and found no
difference in CV hospitalisations (HR, 0.98 (95% CI
0.94 to 1.03)) and CV mortality (HR, 1.05 (95% CI 0.97
to 1.13)) between cardioselective BBs and non-DHP
CCBs.53 An important difference between our study and
most prior studies is that we used an active comparator
group of non-DHP CCB initiators whereas most other
studies compared BB users to non-users. To the best of
our knowledge, only one published randomised trial has
compared the efﬁcacy of cardioselective BBs and
non-DHP CCBs in patients with MI, who also had hyper-
tension, and found similar results for mortality (HR,
1.01 (95% CI 0.87 to 1.16)) and MI (HR, 0.97 (95% CI
0.80 to 1.18)).54 Our mortality and CV hospitalisation
results are in line with comparable bradycardic effects
between cardioselctive BBs and non-DHP CCBs and are
similar to those of the trial; however, given the potential
unmeasured confounding observed for the short-term
COPD hospitalisation outcome, our results are likely biased
downward to the extent that COPD severity and smoking
status, if imbalanced between treatment groups, are also
risk factors for mortality and CV hospitalisations.5 55
A strength of our multinational study is that it permits
examination of heterogeneity in results across databases
and across countries. While the overall summary esti-
mate did not indicate a survival beneﬁt comparing cardi-
oselective BBs to non-DHP CCBs, the database-speciﬁc
HRs for mortality in the US PACE and Italy RER data-
bases were 0.86 (95% CI 0.76 to 0.98) and 0.74 (95% CI
0.64 to 0.85), respectively. These ﬁndings are similar to
those of some prior observational studies.14 16 While it is
possible that this variation in results may be due to true
heterogeneity in treatment effects across databases and
populations, publication of these results in isolation
could have led to very different and potentially mislead-
ing conclusions. The multidatabase approach protects
against this potential problem. As prescribing patterns
and patient characteristics vary across different health
systems and geographical areas, true treatment effects
and confounding can also vary across databases. Results
can also vary across studies due to differences in design
and analytic choices. In contrast to meta-analyses, which
usually combine results from various study designs, our
approach using a common protocol eliminates differ-
ences in design and analytic choices as an explanation
for differences in results across databases.
Our study had several additional limitations. First,
while we used a common protocol to implement our
study across databases, the inherent variations in health-
care systems and data structures across countries necessi-
tated certain database-speciﬁc modiﬁcations to the
protocol. For example, some databases required differ-
ent deﬁnitions for continuous enrolment and different
coding methods for ascertainment of drug use. Also, we
could only access information on inpatient diagnoses in
the RER database, which likely resulted in the identiﬁca-
tion of a more severe COPD population than in the
other databases. Moreover, information on drug days
supply was not available in the RER database, which we
inferred based on the deﬁned daily dose. Second, as
drug data during hospitalisation are usually not available
in healthcare claims databases, we could not accurately
capture inpatient drug information in all ﬁve databases.
Also, patients may not fully adhere to their index drugs
and may add or switch medications during follow-up.
However, our ﬁrst exposure carried forward and
as-treated analyses yielded similar results, which partially
mitigates concerns about exposure misclassiﬁcation.
Third, owing to analytic ﬂexibility, we conducted sensitiv-
ity analyses in the three US databases only. However,
results restricted to these three databases were similar to
the main analyses, which also included the RER and
Taiwan NHI databases. In addition to COPD severity and
smoking status, we could not rule out the inﬂuence of
unmeasured confounding from other clinical para-
meters, such as cardiac function. Finally, previous
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research suggests that non-DHP CCBs may increase the
risk of CHF in patients experiencing acute MI,56 which
may limit non-DHP CCBs as a comparison group.
In conclusion, this multinational study found a strong
inverse association between cardioselective BB use and
COPD hospitalisations, even in the ﬁrst 30 days of
follow-up, suggestive of bias likely due to unmeasured
confounding. This apparent bias persisted across diverse
populations and health systems and could not be fully
removed by state-of-the-art design and analysis methods.
This ﬁnding calls into question the validity of prior
observational studies of the effectiveness of BBs and also
the ability of claims data, in general, to address ques-
tions related to outcomes of BBs in COPD patients. Data
from randomised trials are needed to elucidate the ben-
eﬁts and risks of BBs in patients with COPD.
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